BTK Inhibitor Reduces MS Relapse Rates in Two Phase 3 Trials

30 Oct 2026 0 comments

The BTK inhibitor remibrutnib reduces relapse rates and MRI lesion activity compared with teriflunomide in relapsing MS, although its effect on disability progression remains uncertain.
Medscape Medical News

Source: Medscape Neurology Published 30 Oct 2026 Imported 30 Oct 2026 Relevancy: Not reviewed

Read the article

Comments

No comments yet.

Unrestricted

All comments are reviewed before being published. Most comments are approved unless they are clearly inappropriate or unsafe.

Comments

Leave a comment